Portfolio
5
companies
Aurum Biosciences
Aurum Biosciences develops novel oxygen carriers and diagnostic software for clinical use.
Aveni
Aveni provides real time conversation analytics and automation tools for regulated industries.
Carcinotech
Carcinotech manufactures 3D printed tumours from cancer cells for oncology testing and research.
Kaly
Kaly develops sustainable seaweed farming operations on the Isle of Skye.
Trademylux
Trademylux builds digital resale platforms for luxury goods and fine art.
Jamie Andrew
Chair
Jamie brings extensive board and chair experience, notably with TRICAPITAL and Ranworth Capital. He also serves as a board observer for Gas Sensing Solutions.
LinkedIn
Moray Martin
Managing Partner
Moray leads MB Martin and Partners as founder and CEO, alongside chairing TRICAPITAL Angels. His background includes directorships across solar investment and life sciences firms.
LinkedInTRICAPITAL and Scottish Enterprise backed the funding round to help launch the company's inaugural fine art resale marketplace.
"This is a project we have worked on for several years but was put on ice because of the Covid pandemic and we are now delighted to be supported financially and strategically by TRICAPITAL and Scottish Enterprise."
The Edinburgh biotech uses the capital to scale its 3D bioprinted tumour models across the UK, Europe, and the US.
"Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to accelerate oncology drug development significantly."
TRICAPITAL led the seed round to support the development of seaweed farming operations on the Isle of Skye.
"Kaly aims to add significant capacity to the Scottish seaweed industry in the next few years."
The investment will support the rollout of the Aveni Detect platform across financial services and utilities in the UK.
TRICAPITAL led the investment round with backing from a syndicate of Scottish investors.
"Our next phase of growth will involve building international partnerships, growing the team, and appointing a scientific advisory committee to support the work of the main board."
